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Abstract 
Histoplasmosis, a fungal infection caused by Histoplasma capsulatum (H. capsulatum), acquired 
from contaminated soil with droppings of chicken or birds and found to be distributed in many 
parts of the world. The prevalence of histoplasmosis has not well studied in Nepal. The common 
symptoms of acute and epidemic histoplasmosis include high fever, cough, and asthenia and 
weight loss.  Most of the infections associated with histoplasmosis are asymptomatic. People with 
compromised immune systems such as HIV/AIDS (PLWHA), cancer, and organ transplant 
recipients are at risk of developing this disease. In this review, we have summarised the current 
status of histoplasmosis in Nepal and molecular techniques available for its identification. To date, 
the significant outbreak is not reported in Nepal, but the risk of infection for the vulnerable 
population cannot be undermined. Appropriate preventive measures and treatment on time can 
reduce the burden of this fungal disease. Further, this review is also focused on molecular 
identification of H. capsulatum. Hence, careful considerations by concerned stakeholders for 
national surveillance programs and the treatment of patients on time after proper diagnosis is 
highly recommended.  
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Introduction  
Histoplasmosis is acquired by inhalation of 
spores of H. capsulatum, which is usually found 
in the soil contaminated by bird droppings, 
which reveals the higher risk of disease in 
farmers, gardeners, poultry keepers, 
construction workers, pest control workers and 
in some instances travelers visiting caves and 
tunnels[1]. Histoplasma is a dimorphic fungus, 
which produces mycelial form in the soil 
environment and converts to the yeast form at 
host body temperature (37 °C), and it usually 
does not develop the symptomatic infection. So 
people need not concern about the infection [2]. 
However, for immune-compromised people, 
the fungus can result in severe infection. Very 
young children and elderly people who have a 
weak immune system; are more likely to get 
histoplasmosis disease [3]. 
The development of infection and the 
dissemination of H. capsulatum are initially 
dependent on the condition of the host body[4]. 
The majority of infected persons could have 
either no symptoms or a very less mild sickness, 
which is hard to recognize as the cause of 
histoplasmosis [5]. The clinical symptoms 
generally occur only in a small number (around 
1%) of the population when exposed with H. 
capsulatum spores [6]. Persons who are usually 
immuno-compromised and are unable to 
develop effective cell-mediated response are 
likely to develop symptomatic disease during 
the period of acute dissemination in body [5], 
which includes infant child, patients with 
HIV/AIDS, organ transplant recipients, and 
those with hematologic deficiencies, and also 
those patients, who are on corticosteroids drugs 
treatment [7]. An individual is under the risk of 
developing symptoms even after years leaving 
the endemic vicinity of histoplasmosis if the 
man or woman was in an immuno-suppressive 
situation at that time [8]. Histoplasmosis is of 
four major types: pulmonary histoplasmosis, 
progressive disseminated histoplasmosis, 
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cutaneous histoplasmosis, and African 
histoplasmosis [9, 10]. 
Pathogenesis of Histoplasmosis 
The fungal infection starts after the inhalation of 
spores produced by the mycelial form of H. 
capsulatum and the spores deposited inside the 
alveoli of the lungs [11]. After some time, the 
spores start to germinate inside the alveoli at 
normal body temperature to become dimorphic 
form. Then pulmonary macrophages engulf that 
yeast form of dimorphic fungus [12]. After the 
engulfment, the yeasts become a parasite and 
multiply within the alveolar cells, then travel to 
hilar and mediastinal lymph nodes [13]. When 
yeast form fungus gets access to the blood 
circulation system, then disseminates more 
rapidly and swiftly across various organs of the 
body. About after two weeks of exposure, the 
macrophages become fully fungicidal, then the 
cellular immunity starts a defense against the 
fungal particles [14]. It leads to necrosis at the 
site of infection like in the lungs, liver, spleen, 
lymph nodes, and on bone marrow, adrenal 
glands, and mucocutaneous membranes, which 
results in progressive disseminated 
histoplasmosis [4] as shown in Figure 1. The 
progressive type of histoplasmosis is much 
more lethal and severe as compared to other 
kinds of histoplasmosis [15]. 
Epidemiology 
Histoplasmosis is distributed worldwide, but 
incidence cases are often reported around the 
periphery of river valleys [16]. The majority of 
infections in humans are reported from the 
central United States, whereas the small number 
of cases are also reported from  Brazil, 
Argentina, India, and South Africa [17]. 
Currently, due to an increase in the occurrence 
of histoplasmosis worldwide, scientists have 
been developing several diagnostic strategies. 
Histoplasmosis endemicity can be evaluated by 
population-based use of a histoplasmosis skin 
test [18]. The skin test was found to be useful 
when a major endemic area of histoplasmosis 
identified in the north-eastern and Midwestern 
United States [19]. 
Increased number of infectious diseases like 
histoplasmosis is being reported in areas where 
it was previously not thought to be prevalent, 
and the changing distribution of infectious 
diseases can become an important step to guide 
diagnostic workup and direct public health 
awareness [17]. Notably, in tuberculosis-
endemic regions, disseminated histoplasmosis 
can easily be misdiagnosed as tuberculosis 
because of its similar clinical symptoms and 
must be considered as histoplasmosis infection 
in patients who do not respond to empiric anti-
tubercular therapy [20]. 
An estimated discern indicates that nearly 3,000 
people develop kidney failure yearly in Nepal 
[21]. Similarly, there are additionally a high 
number of the population in Nepal with a 
diabetic condition; the 2016 Diabetes Profile has 
shown that 9.1 %of the Nepali people are 
dwellings with diabetes [22]. Likewise, the cases 
of HIV/AIDS is also in excessive number inside 
the country [23]. According to National Centre 
for AIDS and STD Control (Nepal), there 
are around 31,020 HIV/AIDS sufferers in the 
country, and it is estimated to upward thrust at 
a rate of 2 patients per day. Those persons 
having conditions like a diabetic, organ 
transplant, and the person with HIV/AIDS have 
a weak immune system, which means that they 
are at high risk of developing other secondary 
infections like histoplasmosis during their 
lifetime.  
According to the published reports,  the 
geographical distribution of histoplasmosis has 
not been clearly understood [4]. The occurrence 
of histoplasmosis in Asia has not fully 
appreciated until recently. Malaysia is the first 
country in Asia, where H. capsulatum was 
isolated from soil samples [24]. India, a close 
neighboring of Nepal, has also reported a high 
number of histoplasmosis cases in West Bengal 
and Assam till 2018[24]. From, 1995 to 2018, 
about 388 cases of H. capsulatum has been 
reported, and the number is in increasing order 
in India [24]. In recent years, an increasing 
number of histoplasmosis cases have been 
recognized among HIV-positive and/or 
diabetic patients in India [1]. In case of Nepal, 
histoplasmosis has only been described four 
times, Amatya et al., (2014) reported that the 
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cases of histoplasmosis in an Indian national 
who traveled to Nepal for medical care and once 
in a Nepali citizen, making this the second case 
described in the literature by Subedi et al., (2016) 
[25]. Recently, another case has been published 
by Sharma and Adhikari (2019). According to 
them, a 52 years old man with diabetes shows 
adrenal involvement in histoplasmosis [26]. 
Additionally, one case has reported in a 
Nepalese migrant to the USA with evidence of 
infection being acquired in Nepal by Gandi et 
al., in 2015 [27]. Nepal and India have an open 
border, and a large number of Nepalese 
migrants is directly dependent on Indian 
economic and cultural aspects such as 
employment, education, social relationship, and 
trade among other elements. Such socio-
economic relationship directly has an impact on 
the dissemination of the diseases, including 
histoplasmosis. 
Identification of H. Capsulatum and diagnosis 
of histoplasmosis 
Traditionally, identification of causative agent 
of histoplasmosis is carried out through tissue 
culture or body fluids at 25°C on Sabouraud’s 
dextrose agar to allow the growth of mycelial 
phase of H. capsulatum. For the proper growth of 
mold, it takes about six weeks. After the 
incubation period, two different types of conidia 
are formed. The tuberculate or macroconidia are 
of about 8 – 15 µm in diameter and have a thick 
wall. Similarly, the microconidia are tiny about 
2 -4 µm in diameter and are more infectious 
when compared to the more abundant conidia. 
However, the procedure of culturing is time-
consuming [28]. 
Likewise, histopathological examination is 
another technique for detection of the 
Histoplasma. It is generally done for severely ill 
patients [29]. The method includes tissue 
biopsy. During the histopathological 
observation, other organisms also could mimic 
the appearance like that of H. capsulatum. So, this 
could be eliminated by using another stain like 
methenamine silver or periodic acid- Schiff 
stains, which visualize H. capsulatum [30]. 
Detection of circulating Histoplasma associated 
antigen in urine and serum is another diagnostic 
option to detect the presence of the fungi using 
an immunological technique like sandwich 
enzyme immunoassay (EIA), and it was first 
described in 1986 [31]. This technique generally 
uses H. capsulatum antigen, which is a 
polysaccharide, a polyclonal rabbit anti-
Histoplasma immunoglobulin G linked to biotin, 
and horseradish peroxidase [4, 18]. The assay 
also shows the highest sensitivity against AIDS 
patients who had disseminated histoplasmosis 
[9].  
Antibody tests are also performed to detect 
several forms of Histoplasma cases. There are 
two standard assays for antibody detection they 
are, (i) complement fixation (CF) test, which is 
based on the use of two separate antigens- yeast 
and mycelial (or histoplasmosis)- and (ii) 
immunodiffusion (ID) assay [32]. The ID assay 
tests generally detect the presence of M and H 
precipitin bands. An M 
band often existing in persistent types of 
histoplasmosis and lasts for many months to 
years after the infection. An H band is also 
indicative of the severe form of histoplasmosis 
[17]. The ID assay is approximately only 80% 
sensitive but is more specific than CF assay 
because in CF assay, cross-reaction may occur 
with other fungal infections like sarcoidosis [33]. 
Molecular identification of Histo-
plasmosis 
In recent days, the molecular approach is widely 
used as a reliable and rapid technique for the 
detection of diseases with higher sensitivity and 
specificity. At present, the use of chemo-
luminescence labeled DNA probe for the 
detection of specific sequences of ribosomal 
RNA (rRNA) has been able to detect and 
confirm all the H. capsulatum isolates from the 
culture [32]. AccuProbe is one of them, which is 
based on the principle of nucleic acid 
hybridization. A single-stranded 
chemiluminescent labeled DNA probe is 
complementary to the sequence of ribosomal 
RNA of fungus.  After the rRNA released from 
fungi, the steady DNA-RNA hybrid formed and 
that hybrids are detected and measured by 
using Hologicluminometer. A positive result is 
given by reading equal to or higher than the 
predetermined cut-off values, and an adverse 
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effect is the cost less than that of cut-off values 
[39].  
Polymerase chain reaction (PCR) 
Assay 
PCR is based on the amplification of the fungal 
gene for identifying mycoses. In2003, Guedes et 
al. designed a nested PCR based technique for 
the rapid detection of fungi. The 
oligonucleotides used in this method is based on 
the M - antigens of H. capsulatum var. capsulatum. 
The oligonucleotidesMsp1F - Msp1R (pair 1) and 
Msp2F - Msp2R (pair 2) results amplicon of size 
111 bp and 279 bp, respectively[34]; (Msp1F: 5′ - 
ACA AGA GAC GAC GGT AGC TTC ACG - 3′ 
andMsp1R: 5′ - GCG TTG GGG ATC AAG CGA 
TGA GCC - 3′), (Msp2F: 5′ - CGG GCC GCG TTT 
AAC AGC GCC - 3′ and Msp2R: 5′ - ACC AGC 
GGC CAT AAG GAC GTC - 3′). The PCR 
reaction was performed with 100ng DNA 
amplified in a 25 µl reaction using 20 pmol of 
oligonucleotides(35 cycles of denaturation, 
annealing, and chain extension) [34].  
By using this protocol,100% specificity and 
accuracy were mentioned in the 31 examined 
strains from the animal, soil, and human [34]. 
The results also confirmed the absence of other 
fungal strains such as H. capsulatum var. 
farciminosum, Paracoccidioides brasiliensis, 
Candida spp., Sporothrix schenckii, Cryptococcus 
neoformans,etc in the amplified products[34]. 
Real-time PCR (RT- PCR) 
The real-time RT-PCR or qPCR shows 
promising results in the diagnosis of 
histoplasmosis infection, which currently 
identified the H. capsulatum among several other 
fungi [35]. Simon et al., (2010) carried out 
research for the detection of H. capsulatum based 
on real-time PCR using the TaqMan probe [36]. 
For this study, specific primers and probe 
(TaqManlabeled with fluorescent dye 6-
carboxyfluorescein at 5′ end and a 
nonfluorescent quencher at the 3′ end) were 
used for the analysis of the internal transcribed 
spacer (ITS) region of the rRNA. The 
oligonucleotides HcITS-167F (5′- 
AACGATTGGCGTCTGAGCAT-3′) and HcITS-
229R (5′-GAGATCCGTTGTTGAAAGTTTTGA-
3′) were used. The following probeHcITS-188P 
5′-6- FAM- AGAGCGATAATAATCC- MGB -3′) 
was used. The specificity of RT- PCR was 
calculated to be 95.4% in comparison to the 
culture method. During the process, there is no 
PCR inhibitor detected. Among the 275 samples 
which were previously reported to be negative 
in culture method, 11 samples were reported as 
positive by RT-PCR with a specificity of 96.0%. 
Similarly, among the 341 samples tested, zero 
nonspecific signals were recorded [36].  
Despite this promising research result, for the 
detection of H. capsulatum in clinical samples, 
there are no currently FDA-approved molecular 
assays available. Moreover, to date, the 
molecular approach for the detection of 
histoplasmosis is in a developing stage. 
Similarly, an improved and reliable technique 
has to be designed as a dependable approach for 
the detection of the disease. Regarding the 
future accessibility of molecular techniques for 
the detection of histoplasmosis is not unclouded 
in resource-limited countries like Nepal [37]. 
Treatment of Histoplasmosis 
Based on the current status, most patients with 
mild acute histoplasmosis limited to lungs will 
be resolved after a month without specific 
treatment. However, the disseminated or the 
severe form of histoplasmosis should be treated 
with antifungal agents[17]. 
The treatment of chronic and severe form of 
pulmonary histoplasmosis is generally done by 
prescribing amphotericin B (3.0–5.0 mg/kg 
daily for 1–2 weeks, intravenously), followed by 
itraconazole (200 mg 3 times per day for 3 days 
and after that 200 mg for two times a day, for a 
total of 3 months) is required and 
recommended[38]. Similarly, for progressive 
disseminated histoplasmosis amphotericin B 
(3.0 mg/kg daily) is recommended for about 7-
15days, which is followed by oral drug 
itraconazole having 200 mg concentration for 
daily three times for three days and after that 
200 mg daily for two times for a total of at least 
a year). Likewise, for the patients with the 
immunosuppressed condition, itraconazole 
daily (200 mg) is recommended as 
prophylaxis[19,38]. 
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Research status of histoplasmosis in 
Nepal 
In Nepal, there is poor hygienic practices and 
sanitation in major parts of the country and is 
offering the home for the continuous emergence 
and re-emergence of several life-threatening 
infectious diseases. So, Histoplasmosis could be 
a serious issue of public health in days to come. 
In Nepal, the majority of the population lives in 
rural areas with minimal health care facilities. 
The burden of the disease is much higher in 
rural settings compared to the urban areas. 
Although the pattern of diseases might change 
regularly, infectious diseases remain the leading 
cause of mortality and morbidity in Nepal. In 
many rural settings, cases of some diseases are 
often identified only through their clinical signs 
and symptoms. Lack of proper public health 
awareness and treatment of infectious diseases 
made people prone to several fungal infections, 
including Histoplasmosis, which may be a 
severe issue [40]. As the pervasiveness of 
HIV/AIDS and Tuberculosis are budding 
swiftly, the infection from the Histoplasma may 
lead to a significant effect [41]. Thus, careful 
diagnosis and treatment on time are paramount 
to control the future outbreaks of 
histoplasmosis. Moreover, the probability of 
undiagnosed histoplasmosis dissemination also 
urges for the need of proper diagnostic 
strategies of Histoplasma spp. infection in Nepal. 
As per institutional information, there is no 
routine examination and treatment of 
histoplasmosis infection in Tribhuvan 
UniversityTeaching Hospital and National 
Public Health Laboratory (NPHL-Nepal), while 
both of them are considered as reference health 
service centres of the country.  
Challenges in Nepal 
As Nepal is under the way of development, the 
budgeting for the health and its related sector is 
very less. Lack of proper investment in the 
health sector for the diagnosis and treatment of 
diseases is a significant problem in Nepal. Death 
of hundreds of people by unknown disease is 
also prevalent. Lack of proper government 
strategies and operative ventures in the health 
sector has been a cardinal cause of those strange 
deaths. Allocation of the budget on the health 
sector is only attentive to the treatment of some 
severe disease, which shows that the country 
has less interest in disease diagnosis. It is one of 
the significant consequences of the death of 
people from unknown conditions. Therefore, 
early diagnosis of histoplasmosis is mandatory 
to reduce the burden of illness.  
Conclusion 
The clear and accurate picture of the 
dissemination of histoplasmosis is complicated 
to understand in the resource-limited clinical 
sector of Nepal. Many factors could contribute 
to this, like lack of proper lab facilities, lack of 
expertise on fungal infections, etc. Additionally, 
not much reliable data are available from the 
government and academia due to incompetence 
in the diagnosis strategies. The published data 
are also in the form of case reports based on a 
hospital visit. It is already emphasized that the 
pockets of endemicity do exist in Nepal, which 
could lead to a significant impact on public 
health. Hence, careful considerations and the 
molecular approach of disease identification 
may be a suitable alternative. To address this 
problem, further research should be done 
immediately in Nepal 
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